FDA — authorised 26 March 1999
- Application: NDA020908
- Marketing authorisation holder: NOVO NORDISK INC
- Status: supplemented
FDA authorised Vagifem on 26 March 1999 · 3,114 US adverse-event reports
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Yes. FDA authorised it on 26 March 1999; FDA has authorised it.
NOVO NORDISK INC holds the US marketing authorisation.